Marker Therapeutics, Inc.

Monthly Archives: March 2019

Marker Therapeutics Rockets After CEO Says Phase 2 Leukemia Trial with T-cell Therapy in Works

With the help of Marker’s technology, a population of T-cells attacks multiple cancer targets and works to activate a patient’s immune system to trigger anti-tumor activity.

Read More

Marker Therapeutics Provides Business and Clinical Update

Company to host business update call and webcast today at 5:00 p.m. EDT

Read More

Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th

Marker Therapeutics announces business update conference call and webcast on Thursday, March 28th.

Read More

Marker Therapeutics: Phenomenal Data In Lymphoma And Other Indications, Yet Little Recognition From The Street

DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.

Read More